ONCOMPASS™ IDENTIFIES the mutant cancer genes in your tumor. There are multiple cancer genes, and in each tumor 1 to 8 are mutant. In order to choose the most suitable targeted therapy for you, we must first identify the mutant genes, in your tumor. For this, we use the same tumor tissue sample that was used to diagnose your cancer. We extract DNA from this sample and analyze up to 600 of the most important cancer genes.
ONCOMPASS™ PINPOINTS the best available targeted therapies in the world, today. We have more than 400 targeted drugs in our database. The efficacy of these drugs is cross-referenced with your cancer gene test; we list both the potentially effective and the ineffective drugs. Based on your test results, we also identify the most appropriate current clinical trials targeting your tumor’s specific gene mutations.
ALL THE ONCOLOGISTS can use ONCOMPASS™ to integrate targeted therapies into your personalized treatment strategy. While it is possible that chemotherapy, radiotherapy and surgery is your current best option, ONCOMPASS™ provides information on when and where targeted therapies are available. Working closely with your treating doctor we strategize a treatment plan for you.
An exclusive 58 Gene molecular diagnostic and information service using state of the art analysis and interpretation to find the most suitable targeted therapy. A list of matching global clinical trials, a one-time decision support and recommendations from our Molecular Tumor Board and access to the Precision Medicine Calculator.
A molecular diagnostic service with interpretation for targeted therapies based on the 6-10 therapeutically most relevant mutating genes. The genes are individually selected for each patients; the service also includes a list of potential clinical trials in Europe, a one-time decision support and recommendations from our Molecular Tumor Board and access to the Precision Medicine Calculator.
A molecular diagnostic service with interpretation for targeted therapies based on a panel of almost 600 genes (or even whole exome necessary) covering 100% of the traditionally used panels. The program contains a 5-year decision support for the treating oncologists prior to treatment line changes, recommendations from our Molecular Tumour Board for the treating physician, list of potential clinical trials worldwide and access to the Precision Medicine Calculator.
Evaluation and interpretation of an existing molecular diagnostic test (the diagnostic test is not part of this program). The program contains recommendations from our Molecular Tumour Board for the treating physician, and a collaborative interaction with one of our molecular experts to find the right treatment approach.The service also includes a list of potential clinical trials and access to the Precision Medicine Calculator. Decision support for the treating physician prior to every change in treatment lines can be extended up to 5 years.